Hagop Kantarjian, Professor and Chair of the Department of Leukemia at The University of Texas MD Anderson Cancer Center, shared a post on X:
“Expert recommendations on using MRD in ALL now out in Blood Advances.
ClonoSEQ (NGS MRD) is superior to other MRD methods and should guide decisions about CAR T-cells or SCT.”
Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts
Authors: Nicholas J. Short et al.
